Kaiser Larry 4

What Happened Larry Kaiser, a director of Medicus Pharma Ltd. (MDCX), received a grant of 25,000 derivative shares on March 30, 2026. The Form 4 reports the transaction as an award/grant (transaction code A) at $0.00 per share, so no cash was exchanged. This was an equity award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-30; Form 4 filed: 2026-04-01 (reporting period 2026-03-30).
• Transaction type/code: Award/Grant (A), derivative acquisition.
• Shares acquired: 25,000 shares at $0.00 per share (total reported cash value $0).
• Shares owned after transaction: Not specified in the filing.
• Footnotes/plan details: The filing does not disclose 10b5-1, tax-withholding, or additional footnotes tied to this grant.
• Timeliness: Filed two days after the transaction date; appears to be timely.

Context An "A" (award) derivative entry typically reflects a company grant (e.g., restricted stock units or similar equity compensation) rather than an insider buying stock on the open market. Such grants are common for directors as part of compensation arrangements and do not necessarily indicate a personal purchase or a direct bullish signal by the insider.